IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma

The use of BRAF and MEK inhibitors for patients with BRAF-mutant melanoma is limited as patients relapse on treatment as quickly as 6 months due to acquired resistance. We generated trametinib and dabrafenib resistant melanoma (TDR) cell lines to the MEK and BRAF inhibitors, respectively. TDR cells...

Full description

Saved in:
Bibliographic Details
Main Authors: Hima Patel, Rosalin Mishra, Nour Yacoub, Samar Alanazi, Mary Kate Kilroy, Joan T. Garrett
Format: article
Language:EN
Published: MDPI AG 2021
Subjects:
IR
Online Access:https://doaj.org/article/120f7fae924344028d8f89296f08696d
Tags: Add Tag
No Tags, Be the first to tag this record!